In conclusion, we developed a novel MR-based deep learning algorithm named DeepTEPP, which can accurately predict disease outcomes as well as anti-HER2 targeted treatment benefit, thus to guide further individualized de-escalation and escalation treatment in early HER2-positive breast cancer patients. This evidence concerns the gene ERBB2 and breast cancer.